Conference Call Details:
Toll Free: | 800-909-4985 |
International: | 312-281-1211 |
Conference ID: | 21993618 |
Webcast: | http://public.viavid.com/index.php?id=144542 |
A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com after the conference call.
About
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com.
For more information about
Investor Relations:
646-889-1200
jallaire@lifesciadvisors.com
Chief Financial Officer
908-731-6180
Andrew.Saik@vynetx.com
Source:
2021 GlobeNewswire, Inc., source